donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > MRKR Marker Therapeutics > Detailed Quotes

MRKR Marker Therapeutics

0.491
-0.022-4.20%
Trading Session 08/10 13:11 ET
High
0.500
Open
0.497
Turnover
506.80K
Low
0.463
Pre Close
0.513
Volume
1.06M
Market Cap
41.05M
P/E(TTM)
Loss
52wk High
2.050
Shares
83.60M
P/E(Static)
Loss
52wk Low
0.250
Float Cap
29.35M
Bid/Ask %
-77.78%
Historical High
244.800
Shs Float
59.78M
Volume Ratio
0.10
Historical Low
0.074
Dividend TTM
--
Div Yield TTM
250
P/B
1.15
Dividend LFY
--
Div Yield LFY
50916.50%
Turnover Ratio
1.77%
Amplitude
7.22%
Avg Price
0.479
Lot Size
1
Float Cap
29.35M
Bid/Ask %
-77.78%
Historical High
244.800
Shs Float
59.78M
Volume Ratio
0.10
Historical Low
0.074
Dividend TTM
--
P/B
1.15
Dividend LFY
--
Turnover Ratio
1.77%
Amplitude
7.22%
Avg Price
0.479
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
CEO: Hoang MBA, Peter L.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...